The Europe mRNA Synthesis & Manufacturing Market was valued at $359.36 Million in 2024 and projected to reach to $445.49 Million by 2029, representing a compound annual growth rate of 4.4%. Europe's mRNA synthesis and manufacturing market is positioned for steady expansion through 2029, supported by increasing investments in biopharmaceutical infrastructure and growing demand for mRNA-based therapeutics.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe commands a significant share of the global mRNA synthesis and manufacturing market, valued at $359.36 million in 2024, establishing itself as a critical hub for mRNA technology development and production alongside North America.
Europe's stringent regulatory standards and established pharmaceutical infrastructure provide a competitive advantage, with EMA approval pathways and GMP compliance driving investment in advanced mRNA manufacturing facilities across the region.
The European market is projected to reach $445.49 million by 2029, growing at a CAGR of 4.4%, reflecting sustained demand for mRNA-based therapeutics and vaccines driven by ongoing clinical development and commercialization efforts.
Germany leads European mRNA manufacturing with a market size of $164.1 million, followed by the UK at $108.2 million and France at $68.52 million, reflecting strong biotech ecosystems and manufacturing capabilities across these nations.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | MRNA SYNTHESIS & MODIFICATION SERVICES (Service) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 5.8% from 2024 to 2029 |
| Largest Segment | CONSUMABLES (Product) |
| Market Size Base Year (Billions) | ~USD 2.23 (2024) |
| Revenue Forecast (Billions) | ~USD 2.96 (2029) |
| Segments Covered | Product, Type, Application, End User, Service, Consumables, Transcription Consumables, Purification Consumables, Analysis & Characterization Consumables |
9 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTIONS | 11.8 | 10.1 | 9.9 | 10.2 | 10.6 | 11.2 | 11.8 | 12.7 | 5.1 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 33.6 | 28.7 | 28.5 | 29.3 | 30.7 | 32.4 | 34.4 | 37.2 | 5.5 |
| SMALL-SCALE CROS & CDMOS | 4 | 3.4 | 3.3 | 3.4 | 3.5 | 3.6 | 3.8 | 4.1 | 4.2 |
| TOTAL | 49.4 | 42.1 | 41.8 | 42.9 | 44.9 | 47.2 | 50 | 54 | 5.3 |
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTIONS | 129.6 | 94.6 | 94.7 | 97.6 | 101.9 | 106.5 | 111.2 | 117.6 | 4.4 |
| CROS & CDMOS | 110.8 | 80.8 | 80.8 | 83.3 | 86.9 | 90.7 | 94.6 | 100 | 4.3 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 306.2 | 223.7 | 224.5 | 231.8 | 242.5 | 253.7 | 265.4 | 281.2 | 4.6 |
| TOTAL | 546.7 | 399 | 400.1 | 412.7 | 431.3 | 450.8 | 471.1 | 498.7 | 4.5 |
| Country | 2025 size (native) |
|---|---|
| Germany | USD 164.1 Million |
| UK | USD 108.2 Million |
| France | USD 68.52 Million |
| Switzerland | USD 36.54 Million |
| Italy | USD 16.63 Million |
| Spain | USD 14.62 Million |
| Rest Of Europe | USD 65 Million |
Europe's mRNA synthesis and manufacturing market was valued at $359.36 million in 2024 and is expected to grow to $445.49 million by 2029.
Europe's mRNA synthesis and manufacturing market is projected to grow at a compound annual growth rate (CAGR) of 4.4% from 2024 to 2029.
Germany, Switzerland, and the United Kingdom are among the key European markets driving innovation and growth in mRNA synthesis platforms and contract manufacturing services.
Growth in Europe is driven by strong regulatory frameworks, increased healthcare expenditures, government support for biopharmaceutical manufacturing, expanding vaccine production capacity, and growing clinical applications of mRNA therapeutics.
Europe's regulatory bodies, particularly the European Medicines Agency (EMA), have implemented streamlined approval pathways for mRNA products, accelerating market entry and commercialization of mRNA-based therapeutics and vaccines.
The study involved major activities in estimating the current market size for the mRNA synthesis and manufacturing market. Exhaustive secondary research was done to collect information on the mRNA synthesis and manufacturing industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as market share analysis, MnM repository analysis, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the mRNA synthesis and manufacturing market.
The market for the companies offering mRNA synthesis and manufacturing solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product & service portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases. In the secondary research process, various secondary sources were referred to for identifying and collecting information related to the study. Secondary sources included annual reports, press releases, and investor presentations of blockchain vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and product-oriented perspectives.
Extensive primary research was conducted after acquiring basic knowledge about the global mRNA synthesis and manufacturing market scenario. Several primary interviews were conducted with market experts from both the demand side (such as personnel from the pharmaceutical & biopharmaceutical industry) and the supply side (such as C-level and D-level executives, product managers, marketing and sales managers of key manufacturers, distributors, as well as channels) across five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, and online, personal, and telephonic interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Top-down approache was used to estimate and validate the total size of the mRNA synthesis and manufacturing market. These methods include market share analysis, MnM repository analysis were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.
mRNA synthesis and manufacturing refers to the process of producing messenger RNA (mRNA) through in vitro transcription, followed by various purification, and characterization steps to create high-quality mRNA products suitable for research, therapeutic, or vaccine applications. The mRNA synthesis and manufacturing market encompasses the development, production, and commercialization of messenger RNA (mRNA) products, including their synthesis via in vitro transcription, large-scale manufacturing, and formulation. This market serves various applications such as vaccines, therapeutic treatments, and potentially other areas like protein replacement. It involves specialized technologies and equipment, adherence to regulatory standards, and a global supply chain network.
The study provides an in-depth analysis of the mRNA synthesis and manufacturing market based on contemporary market trends and developments, and its potential growth from 2024 to 2029. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key mRNA synthesis and manufacturing product and service providers.
Full forecast, segment splits, and company analysis for all mRNA Synthesis & Manufacturing Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report